Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）有没有毒？

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）有没有毒？看完这些文献就懂了

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt，CAS号:115144-35-9）有没有毒？Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt，货号MB000102-R70170或MB102-R70170），是一款被用于动物体内实验、在国外已经受到检验的产品。这间接说明，Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）在质量和价格上都很有竞争优势。Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）目前已经登陆中国市场，有意进入中国高校的动物实验中心和实验室。

Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt，货号：MB000102-R70170或MB102-R70170）凭借其卓越的性能，得到了欧美众多大学core facilities的科研人员的肯定与青睐。Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）的卓越成效不仅在欧美各大实验室的动物体内实验中得到了验证，更在国际权威学术期刊频频被提及，彰显了其为生命科学领域研究的重要贡献。Syd Labs D-荧光素钾盐（D-Luciferin Potassium Salt）作为一项科研领域的重要实验材料之一，被下方两篇文献引用：

24.

Inhibition of aberrant tissue remodelling by mesenchymal stromal cells singly coated with soft gels presenting defined chemomechanical cues

Sing Wan Wong, Chandramohan R Tamatam, Ik Sung Cho, Peter T Toth, Raymond Bargi, Patrick Belvitch, James C Lee, Jalees Rehman, Sekhar P Reddy, Jae-Won Shin

Nat Biomed Eng. 2022 Jan;6(1):54-66. doi: 10.1038/s41551-021-00740-x. Epub 2021 Jun 3.

One week after bleomycin treatment, uncoated or gel-coated firefly luciferase expressing D1 mouse MSCs were delivered via i.t. or i.v. routes. The mice were then i.v. injected with 200 μl of 15 mg ml−1 D-luciferin (Syd Labs) in PBS per 20 g mouse at different time points, followed by bioluminescence imaging with the IVIS Spectrum (PerkinElmer) within 10 min of D-luciferin injection to measure an average radiance (photons s−1 cm−2 sr−1) in the lung region using the Living Image software (4.0, PerkinElmer).

25.

Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy

Zhefu Dai, Xiao-Nan Zhang, Qinqin Cheng, Fan Fei, Tianling Hou, Jiawei Li, Alireza Abdolvahabi, Junji Watanabe, Hua Pei, Goar Smbatyan, Jianming Xie, Heinz-Josef Lenz, Stan G Louie, Yong Zhang

J Control Release. 2021 Aug 10:336:433-442. doi: 10.1016/j.jconrel.2021.06.041. Epub 2021 Jun 29.

In Vivo Efficacy Study. Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice at age of 6 weeks were purchased from the Jackson Laboratory (ME, USA). Each mouse was inoculated with 1 million luciferase-expressing U937 cells in 200 μL DPBS by tail vein I.V. injection. On day 2 post U937 cells implantation, mice were randomized into 5 per group and given 150 mg kg-1 of D-luciferin (Syd Labs, MA, USA), followed by imaging using an IVIS Lumina III Imaging System (PerkinElmer, MA, USA) for luminescence generated by luciferase-expressing U937 cells. On days 4, 7, and 10 post U937 cells inoculation, different groups of mice were given one of the following treatment options: (1) 200 µL of DPBS (vehicle only); (2) DAR4-ARC-IgG at 5 mg kg-1; (3) DAR2-ARC-ADC at 1 mg kg-1; (4) DAR2-ARC-ADC at 5 mg kg-1; (5) DAR4-ARC-ADC at 1 mg kg-1; (6) DAR4-ARC-ADC at 5 mg kg-1. In order to conduct both the interimefficacy analysis (when conditions of control group mice reach the endpoint per IACUC protocol) based on tissue sample analysis by flow cytometry as well as study for survival difference between groups, 2 groups of mice were given treatment option (3), (4), (5) or (6) with one group for interim efficacy analysis while the other group for survival analysis. Since the completion of first IVIS imaging, all live mice were continued to be imaged by IVIS weekly.